ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION
Top Cited Papers
Open Access
- 26 April 2007
- journal article
- review article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 34 (9) , 906-911
- https://doi.org/10.1111/j.1440-1681.2007.04638.x
Abstract
1 Arginase is the focal enzyme of the urea cycle hydrolysing l‐arginine to urea and l‐ornithine. Emerging studies have identified arginase in the vasculature and have implicated this enzyme in the regulation of nitric oxide (NO) synthesis and the development of vascular disease. 2 Arginase inhibits the production of NO via several potential mechanisms, including competition with NO synthase (NOS) for the substrate l‐arginine, uncoupling of NOS resulting in the generation of the NO scavenger, superoxide and peroxynitrite, repression of the translation and stability of inducible NOS protein, inhibition of inducible NOS activity via the generation of urea and by sensitization of NOS to its endogenous inhibitor asymmetric dimethyl‐l‐arginine. 3 Upregulation of arginase inhibits endothelial NOS‐mediated NO synthesis and may contribute to endothelial dysfunction in hypertension, ageing, ischaemia–reperfusion and diabetes. 4 Arginase also redirects the metabolism of l‐arginine to l‐ornithine and the formation of polyamines and l‐proline, which are essential for smooth muscle cell growth and collagen synthesis. Therefore, the induction of arginase may also promote aberrant vessel wall remodelling and neointima formation. 5 Arginase represents a promising novel therapeutic target that may reverse endothelial and smooth muscle cell dysfunction and prevent vascular disease.Keywords
This publication has 77 references indexed in Scilit:
- Modulation of contractility by myocyte-derived arginase in normal and hypertrophied feline myocardiumAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Knockdown of Arginase I Restores NO Signaling in the Vasculature of Old RatsHypertension, 2006
- Isolation of human liver arginase cdna and demonstration of nonhomology between the two human arginase genesPublished by Elsevier ,2005
- Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteriesAtherosclerosis, 2005
- Upregulation of Vascular Arginase in Hypertension Decreases Nitric Oxide–Mediated Dilation of Coronary ArteriolesHypertension, 2004
- Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertensionThe FASEB Journal, 2004
- Ischemia‐reperfusion selectively impairs nitric oxide‐ mediated dilation in coronary arterioles: counteracting role of arginaseThe FASEB Journal, 2003
- Increased Expression of Arginase II in Human Diabetic Corpus Cavernosum: In Diabetic-Associated Erectile DysfunctionBiochemical and Biophysical Research Communications, 2001
- The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusionCardiovascular Research, 1996
- Nω-Hydroxy-L-Arginine, an Intermediate in the L-Arginine to Nitric Oxide Pathway, Is a Strong Inhibitor of Liver and Macrophage ArginaseBiochemical and Biophysical Research Communications, 1994